Workflow
Efzofitimod
icon
Search documents
ATYR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that aTyr Pharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Globenewswire· 2025-10-12 16:00
Core Viewpoint - A class action lawsuit has been filed against aTyr Pharma, Inc. for alleged violations of federal securities laws during the specified class period [1][2][3]. Group 1: Lawsuit Details - The lawsuit seeks to recover damages for investors who purchased aTyr securities between January 16, 2025, and September 12, 2025 [2]. - The Complaint alleges that aTyr's executives made materially false and misleading statements regarding the drug Efzofitimod, particularly about its efficacy and the ability for patients to taper steroid usage [3]. Group 2: Next Steps for Investors - Investors who suffered losses in aTyr have until December 8, 2025, to request to be appointed as lead plaintiff in the case [4]. - A copy of the Complaint can be reviewed on the law firm's website [4]. Group 3: Legal Representation - The law firm operates on a contingency fee basis, meaning they will only seek reimbursement for expenses and fees if successful in the lawsuit [5]. - Bronstein, Gewirtz & Grossman, LLC is recognized for representing investors in securities fraud class actions and has recovered hundreds of millions for investors [6].
INVESTOR DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma
Businesswire· 2025-10-12 13:09
NEW YORK--(BUSINESS WIRE)--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against aTyr Pharma, Inc. ("aTyr†or the "Company†) (NASDAQ: ATYR) and reminds investors of the December 9, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds ...
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages aTyr Pharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATYR
Globenewswire· 2025-10-12 12:44
NEW YORK, Oct. 12, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of aTyr Pharma, Inc. (NASDAQ: ATYR) between January 16, 2025 and September 12, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 8, 2025. SO WHAT: If you purchased aTyr Pharma common stock du ...
ATYR Investor Notice: Robbins LLP Reminds Investors of the Securities Fraud Class Action Against aTyr Pharma, Inc.
Globenewswire· 2025-10-10 23:24
Core Points - A class action has been filed on behalf of investors who purchased aTyr Pharma, Inc. common stock between January 16, 2025, and September 12, 2025 [1] - The allegations involve misleading statements regarding the efficacy of aTyr's drug candidate, Efzofitimod, during a Phase 3 clinical trial for pulmonary sarcoidosis [2] - Following the announcement that the EFZO-FIT study did not meet its primary endpoint, aTyr's stock price plummeted by 83.2%, from $6.03 to $1.02 per share in one day [3] Company Overview - aTyr Pharma, Inc. is a clinical stage biotechnology company focused on developing therapies for fibrosis and inflammation through evolutionary intelligence [1] Legal Proceedings - Shareholders wishing to serve as lead plaintiffs in the class action must submit their papers by December 8, 2025 [4] - The representation in the class action is on a contingency fee basis, meaning shareholders incur no fees or expenses [5]
ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit
Prnewswire· 2025-10-10 21:01
Core Viewpoint - Rosen Law Firm has announced the filing of a class action lawsuit on behalf of purchasers of aTyr Pharma, Inc. common stock during the specified Class Period, highlighting potential investor compensation opportunities [1][2]. Group 1: Class Action Details - The class action lawsuit pertains to aTyr Pharma, Inc. common stock purchases made between January 16, 2025, and September 12, 2025 [1]. - Investors who purchased shares during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A lead plaintiff must move the Court by December 8, 2025, to represent other class members in the litigation [1][3]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as the Rosen Law Firm has significant experience and success in this area [4]. - The firm has achieved notable settlements, including the largest securities class action settlement against a Chinese company at the time, and has recovered hundreds of millions for investors [4]. Group 3: Case Allegations - The complaint alleges that defendants made misleading statements regarding the efficacy of Efzofitimod, particularly concerning its ability to allow patients to taper steroid usage completely [5]. - The lawsuit claims that when the true details were revealed, investors suffered damages due to the misleading information [5].
aTyr Pharma, Inc. (ATYR) Securities Class Action Deadline Alert: Shamis & Gentile, P.A. Alerts Investors of Important Lead Plaintiff Deadline of December 8, 2025
Globenewswire· 2025-10-10 16:18
MIAMI, Oct. 10, 2025 (GLOBE NEWSWIRE) -- The law firm of Shamis & Gentile, P.A. alerts investors that a securities class action lawsuit has been filed against aTyr Pharma, Inc. (NASDAQ: ATYR) on behalf of investors who purchased or otherwise acquired aTyr Pharma common stock between January 16, 2025 and September 12, 2025, inclusive. The lead plaintiff deadline for this action is December 8, 2025. For more information go to:aTyr Pharma Securities Class Action    Impacted investors may also contact attorney ...
Stockholder Alert: Robbins LLP Informs aTyr Pharma, Inc. Stockholders that a Class Action Lawsuit was Filed Against the Company
Prnewswire· 2025-10-10 05:12
Core Viewpoint - Robbins LLP has initiated a class action lawsuit on behalf of investors who purchased aTyr Pharma, Inc. common stock between January 16, 2025, and September 12, 2025, alleging that the company misled investors regarding the efficacy of its drug candidate, Efzofitimod [1][2]. Allegations - The lawsuit claims that aTyr Pharma provided misleading information about the Phase 3 study of Efzofitimod, which was designed to evaluate its safety and efficacy in patients with pulmonary sarcoidosis. The company's executives expressed confidence in the study's design while allegedly concealing the drug's inability to allow patients to taper off steroids completely [2]. - On September 15, 2025, aTyr announced that the EFZO-FIT study did not meet its primary endpoint, specifically the change from baseline in mean daily OSC dose at week 48. Following this announcement, the stock price plummeted from $6.03 per share on September 12, 2025, to $1.02 per share on September 15, 2025, marking an 83.2% decline in a single day [3]. Next Steps - Shareholders interested in serving as lead plaintiffs in the class action must submit their papers to the court by December 8, 2025. Participation in the case is not required to be eligible for recovery, and shareholders can choose to remain absent class members [4]. About Robbins LLP - Robbins LLP is recognized for its leadership in shareholder rights litigation, focusing on helping shareholders recover losses and improve corporate governance since 2002 [5].
aTyr Pharma, Inc.'s (ATYR) Failed Drug Trial Spurs Securities Lawsuit -- Hagens Berman
Prnewswire· 2025-10-10 02:18
Core Viewpoint - A federal class-action lawsuit has been filed against aTyr Pharma, Inc. following an 83% drop in its stock price after its lead drug candidate failed to meet primary endpoints in a Phase 3 trial [1][7]. Group 1: Lawsuit Details - The lawsuit, titled Munguia v. aTyr Pharma Inc., alleges that aTyr and its executives made false and misleading statements regarding the efficacy of its drug Efzofitimod, leading to inflated stock prices [2][5]. - The proposed class includes all investors who acquired aTyr common stock between January 16, 2025, and September 12, 2025 [3]. - The allegations center around aTyr's Phase 3 study, EFZO-FIT, which evaluated Efzofitimod in patients with pulmonary sarcoidosis [3]. Group 2: Company Statements and Market Reaction - Throughout the class period, aTyr executives expressed confidence in the study's design and the drug's potential to reduce steroid dependency [4]. - The lawsuit claims that while making optimistic statements, aTyr was concealing adverse facts about Efzofitimod's efficacy, which constitutes a violation of securities laws [5]. - The negative results from the EFZO-FIT study were disclosed on September 15, 2025, leading to a drastic decline in stock price from $6.03 to $1.02, a drop of 83.2% [6][7]. Group 3: Investigation and Market Opportunity - Hagens Berman is investigating whether aTyr misled investors regarding trial data and the drug's market potential, which was emphasized as a multi-billion-dollar opportunity [8]. - The firm is urging investors who suffered losses or have relevant information to come forward [9].
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of aTyr Pharma, Inc. Common Stock and Sets a Lead Plaintiff Deadline of December 8, 2025
Globenewswire· 2025-10-09 20:24
NEW YORK, Oct. 09, 2025 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired common stock of aTyr Pharma, Inc. (“aTyr” or the “Company”) (NASDAQ: ATYR) between January 16, 2025, and September 12, 2025, inclusive. You are hereby notified that the class action lawsuit Marco Munguia v. aTyr Pharma, Inc., et al. (Case No. 3:25-cv-02681) has been commenced in the United States District Court for the Southern District ...
aTyr Pharma, Inc. (NASDAQ:ATYR) Downgraded by RBC Capital
Financial Modeling Prep· 2025-09-16 05:03
Company Overview - aTyr Pharma, Inc. is a biotechnology company focused on developing innovative medicines for patients with rare diseases, particularly working on Efzofitimod for pulmonary sarcoidosis [1] - The company operates in a challenging and volatile biotech sector, especially within the rare disease treatment space [1] Recent Developments - On September 15, 2025, RBC Capital downgraded aTyr Pharma's stock from "Outperform" to "Sector Perform" following the Phase III EFZO-FIT study results of Efzofitimod [2][5] - The stock price at the time of the downgrade was $1.01, reflecting a significant decrease of 83.17% from previous levels, with a change of $5.01 [2] Market Reaction - The announcement of the Phase III EFZO-FIT study results led to significant fluctuations in aTyr's stock, which ranged from a low of $1 to a high of $1.37 on the day of the announcement [3] - The stock has experienced considerable volatility over the past year, with highs of $7.29 and lows of $1, indicating the challenges faced by biotech firms [4] Financial Metrics - aTyr Pharma has a market capitalization of approximately $99.46 million, highlighting the volatility and challenges in the biotech sector, particularly for companies focused on rare diseases [4][5] - The trading volume for aTyr Pharma was reported at 152.6 million shares, further illustrating the active trading environment surrounding the stock [4]